Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.
The validation of flow cytometry analysis of anti-live trypomastigote antibodies (FC-ALTA) to monitor cure after treatment of Chagas' disease was evaluated with serum samples from treated and nontreated chagasic patients. After optimization of the original technique, toward better sensitivity and applicability to field surveys, we design a double blind study of 94 coded samples classified into the following categories: patients not treated (NT) and patients treated but not cured (TNC), both presenting positive conventional serology and xenodiagnosis; patients treated and cured (TC), showing negative serology and xenodiagnosis; and patients treated under evaluation (TUE), who presented positive or oscillating conventional serology (CSA) but negative xenodiagnosis. Coded samples, diluted 1:256, were assayed by incubation with live cell culture trypomastigotes, which were subsequently stained with fluorescein isothiocyanate-conjugated anti-human immunoglobulin G, with prior fixation and analysis by flow cytometry. The results were expressed as the percentages of positive fluorescent parasites (PPFP) for each individual sample, establishing 20% PPFP as the cutoff between negative and positive results. Our data demonstrated that all NT and TNC presented positive results while all but one TC had a PPFP lower than 20%. Analysis of TUE demonstrated a wide degree of reactivity, with PPFP values that were negative (PPFP </= 20%), low positive (20% < PPFP </= 50%), and high positive (PPFP > 50%). As TUE with negative PPFP presented negative xenodiagnosis and positive or oscillating CSA, they were classified as dissociated according to the criteria of Krettli and Brener (J. Immunol. 128:2009-2012, 1982) and could indeed be considered cured after chemotherapy. This study demonstrates and validates the use of FC-ALTA to easily identify anti-live trypomastigote membrane-bound antibodies, offering another approach for investigating and monitoring the efficacy of specific chemotherapy in cases of human Chagas' disease.
Martins-Filho
Olindo Assis
OA
Laboratório de Doença de Chagas, Centro de Pesquisas René Rachou, FIOCRUZ, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. oamfilho@cpqrr.fiocruz.br
Eloi-Santos
Silvana Maria
SM
Teixeira Carvalho
Andréa
A
Oliveira
Rodrigo Corrêa
RC
Rassi
Anis
A
Luquetti
Alejandro Ostemayer
AO
Rassi
Gustavo Gabriel
GG
Brener
Zigman
Z
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis*; D014355:Chagas Disease / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003451:Cryoprotective Agents; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D005434:Flow Cytometry / Q000379:methods* / Q000592:standards; D005990:Glycerol; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D013696:Temperature; D014349:Trypanosoma cruzi / Q000276:immunology*
D000913:Antibodies, Protozoan; D003451:Cryoprotective Agents; D005990:Glycerol